- Home
- IMRN vs POAI Comparison
IMRN vs POAI Comparison
Compare IMRN & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- POAI
- Stock Information
- Founded
- IMRN 1994
- POAI 2002
- Country
- IMRN Australia
- POAI United States
- Employees
- IMRN N/A
- POAI N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- IMRN Health Care
- POAI Health Care
- Exchange
- IMRN Nasdaq
- POAI Nasdaq
- Market Cap
- IMRN 9.2M
- POAI 7.8M
- IPO Year
- IMRN N/A
- POAI N/A
- Fundamental
- Price
- IMRN $1.80
- POAI $1.00
- Analyst Decision
- IMRN Strong Buy
- POAI Hold
- Analyst Count
- IMRN 1
- POAI 1
- Target Price
- IMRN $5.00
- POAI N/A
- AVG Volume (30 Days)
- IMRN 46.0K
- POAI 129.3K
- Earning Date
- IMRN 08-29-2025
- POAI 11-11-2025
- Dividend Yield
- IMRN N/A
- POAI N/A
- EPS Growth
- IMRN N/A
- POAI N/A
- EPS
- IMRN N/A
- POAI N/A
- Revenue
- IMRN $4,777,422.00
- POAI $1,664,696.00
- Revenue This Year
- IMRN N/A
- POAI $486.27
- Revenue Next Year
- IMRN N/A
- POAI $65.50
- P/E Ratio
- IMRN N/A
- POAI N/A
- Revenue Growth
- IMRN 48.63
- POAI 71.65
- 52 Week Low
- IMRN $1.50
- POAI $0.55
- 52 Week High
- IMRN $2.87
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- IMRN 48.13
- POAI 61.64
- Support Level
- IMRN $1.80
- POAI $0.90
- Resistance Level
- IMRN $1.94
- POAI $1.05
- Average True Range (ATR)
- IMRN 0.08
- POAI 0.08
- MACD
- IMRN -0.01
- POAI 0.00
- Stochastic Oscillator
- IMRN 22.22
- POAI 65.74
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.